Dr. Weeks’ Comment: Finally remedies are being developed to target the lethal cancer STEM cells.
“…The present invention relates to targeting the Cancer Stem Cell (CSC) and Circulating Tumor Cells (CTCs) population within the human pancreatic tumor…”
Celprogen Introduces a Novel Pharmacological Inhibitor CEP1430 for Human Pancreatic Cancer Patients
- Published on Wednesday, 15 April 2015 08:22
Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed a novel pharmacological Inhibitor CEP1430 synthetic molecule that is capable of inhibiting the growth and proliferation of the human pancreatic cancer tumor. This molecule can be administrated by the following methods: intravenous and intra-peritoneal. The molecule CEP1430 will be presented at the American Association for Cancer Research Annual Meeting in Philadelphia, Tuesday, April 21, 2015, 1:00 PM – 5:00 PM; Therapeutics Targeting Cancer Stem Cells.
The present invention relates to targeting the Cancer Stem Cell (CSC) and Circulating Tumor Cells (CTCs) population within the human pancreatic tumor. The novel pharmacological inhibitor molecule CEP1430 has been developed and optimized by Celprogen utilizing cancer stem cell drug discovery high throughput screening technology. This technology has generated approximately 10 lead compounds for targeted cancer therapy for pancreatic cancer patients. Our preclinical results show that CEP1430 is efficacious against Pancreatic CSC and CTCs without adverse effects at doses tested. CEP1430 reduced the tumor volume in the treated group by 80-90% in comparison to control.